PROM1 and neoplasm: Furthermore, CAR-NK92 cells targeting CD133, when used with cisplatin, exhibit significant anti-tumor effects in ovarian cancer, with cisplatin not affecting the cytotoxicity or viability of CAR-NK cells (68).